Topics:

PhI data puts Novartis on track to deliver H7N9 vaccine

November 21, 2013 | By
Tools

Novartis ($NVS) has posted positive Phase I data for its H7N9 vaccine, which is now in large-scale production. The trial found two doses of the adjuvanted cell culture vaccine immunologically protected 85% of participants. Release

Filed Under
, ,

Comments

Press Releases
  • Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
  • Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market
  • Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
  • Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market
  • Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.